This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase 3

Phase 2

  • Mirikizumab
    LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of immune diseases including ulcerative colitis and psoriasis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Dual Amylin Calcitonin Receptor Agonist
    DACRA-042 is a new biologic entity that acts as a dual agonist of both the amylin receptor and calcitonin receptor and is being studied for the treatment of diabetes.

    For more information on DACRA-042 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • GIP/GLP-1 Co-Agonist Peptide
    LY3298176 (GIP/GLP-1 Co-agonist Peptide) is a new biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.

    For more information on LY3298176 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 1

  • BAFF/IL-17 Bispecific Antibody
    "BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • CXCR1/2 Ligands Antibody
    "CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-2 PEG
    "IL-2 PEG" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-21 Antibody
    "IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • Dual Amylin Calcitonin Receptor Agonist
    "DACRA-089" is a new biologic entity being studied for the treatment of diabetes.

     
  • Insulin-Fc/Dula
    "Basal insulin-Fc" is a new biologic entity being studied for the treatment of diabetes.

     
  • Insulin Basal Long Acting
    "Insulin basal long acting" is a new biologic entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  • Oxyntomodulin
    "Oxyntomodulin" is a new biologic entity being studied for the treatment of diabetes.

     
  • Aß42 Antibody
    "Aß42 antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Ab Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody + LY Combo
    "PD-L1 Antibody" is a new biologic entity being studied for development in combination for the treatment of cancer.

     
  • TIM-3 MAb
    "TIM-3 MAb " is a new biologic entity being studied for the treatment of cancer.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of October 17, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • Select NME
  • Select NILEX
  • Diagnostic
GTM-PQNKVL